{
    "clinical_study": {
        "@rank": "129555", 
        "arm_group": [
            {
                "arm_group_label": "Population A", 
                "arm_group_type": "Experimental", 
                "description": "A total of 9 groups in two population. Population A comprises hypercholesterolemic Japanese subjects whose LDL-C is not controlled by a stable dose of atorvastatin. A subject who is receiving a stable dose of atorvastatin will be randomized into one out of 5 dose groups."
            }, 
            {
                "arm_group_label": "Population B", 
                "arm_group_type": "Experimental", 
                "description": "A total of 9 groups in two population. Population B comprises hypercholesterolemic Japanese subjects who are na\u00efve for a treatment by lipid lowering drug and whose fasting LDL-cholesterol is not controlled. A subject who is treatment na\u00efve will be randomized into one out of 4 dose groups."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the low density lipoprotein cholesterol (LDL-C)\n      lowering effect of PF-04950615 administered subcutaneously at every two weeks (Q14D) in\n      hypercholesterolemic Japanese subjects whose LDL-C is not controlled by a stable dose of\n      atorvastatin, or who are na\u00efve to a treatment by lipid lowering drug and whose LDL-C is not\n      controlled."
        }, 
        "brief_title": "Dose Ranging Study Of PF-04950615 In Hypercholesterolemic Japanese Subjects", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypercholesterolemia", 
        "condition_browse": {
            "mesh_term": "Hypercholesterolemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects whose LDL-C is not controlled by a stable dose of atorvastatin (Population\n             A).\n\n          -  Subjects who are na\u00efve to a treatment by lipid lowering drug and whose LDL-C is not\n             controlled (Population B).\n\n        Exclusion Criteria:\n\n          -  Severe acute or chronic medical or psychiatric condition or laboratory abnormality.\n\n          -  Pregnant females; breastfeeding females; males and females of childbearing potential;\n             males and females of childbearing potential who are unwilling or unable to use a\n             highly effective method of contraception.\n\n          -  Subjects who were administered or prior exposed to PF-04950615 and/or anti-body\n             targeting PCSK9."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "216", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02055976", 
            "org_study_id": "B1481036"
        }, 
        "intervention": [
            {
                "arm_group_label": "Population A", 
                "description": "Atorvastatin plus PF-04950615 50 mg subcutaneous administration at every two weeks (Q14D SC) for 16 week", 
                "intervention_name": "PF-04950615", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Population A", 
                "description": "Atorvastatin plus PF-04950615 100 mg Q14D SC for 16 week", 
                "intervention_name": "PF-04950615", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Population A", 
                "description": "Atorvastatin plus PF-04950615 150 mg Q14D SC for 16 week", 
                "intervention_name": "PF-04950615", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Population A", 
                "description": "Atorvastatin plus PF-04950615 Placebo Q14D SC for 16 week", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Population A", 
                "description": "Atorvastatin plus Ezetimibe 10 mg oral administration once daily for 16 week (open)", 
                "intervention_name": "Ezetimibe", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Population B", 
                "description": "PF-04950615 50 mg Q14D SC for 16 week", 
                "intervention_name": "PF-04950615", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Population B", 
                "description": "PF-04950615 100 mg Q14D SC for 16 week", 
                "intervention_name": "PF-04950615", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Population B", 
                "description": "PF-04950615 150 mg Q14D SC for 16 week", 
                "intervention_name": "PF-04950615", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Population B", 
                "description": "PF-04950615 Placebo Q14D SC for 16 week", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Atorvastatin", 
                "Ezetimibe"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "PF-04950615", 
            "Japan"
        ], 
        "lastchanged_date": "May 14, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1481036&StudyName=Dose%20Ranging%20Study%20Of%20PF-04950615%20In%20Hypercholesterolemic%20Japanese%20Subjects"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Maebashi", 
                        "country": "Japan", 
                        "state": "Gunma"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yokohama", 
                        "country": "Japan", 
                        "state": "Kanagawa"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suita", 
                        "country": "Japan", 
                        "state": "Osaka"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chiyoda-ku", 
                        "country": "Japan", 
                        "state": "Tokyo"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shinjuku-ku", 
                        "country": "Japan", 
                        "state": "Tokyo"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toshima-ku", 
                        "country": "Japan", 
                        "state": "Tokyo"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2 Double Blind, Parallel Group, Placebo Controlled, Randomized, Dose Ranging Study To Assess The Efficacy, Safety And Tolerability Of PF-04950615 Following Twice Monthly Subcutaneous Doses In Hypercholesterolemic Japanese Subjects Who Are Receiving A Stable Dose Of Atorvastatin Or Treatment Na\u00efve", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percent Change from Baseline in LDL-C at Week 12 and 16", 
            "safety_issue": "No", 
            "time_frame": "Week 12 and 16"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02055976"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Actual Value and Change from Baseline in LDL-C", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12 and 16"
            }, 
            {
                "description": "Total Cholesterol (TC), ApoB, ApoA-I, ApoA-II, Lp(a), High Density Lipoprotein Cholesterol, VLDL-C, Triglyceride, Non-HDL-cholesterol, TC/HDL-C ratio and ApoB/ApoA-I ratio.", 
                "measure": "Actual Value, Change from Baseline and Percent Change from Baseline in Lipid parameters", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12 and 16"
            }, 
            {
                "measure": "Proportion of subjects having LDL-C less than particular limits (<100 mg/dL, <70 mg/dL, <40 mg/dL, <25 mg/dL, <10 mg/dL)", 
                "safety_issue": "No", 
                "time_frame": "Week 12 and 16"
            }, 
            {
                "measure": "Anti-drug antibody (ADA)", 
                "safety_issue": "Yes", 
                "time_frame": "Week 24"
            }, 
            {
                "measure": "Area Under the Curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Week 20"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Week 20"
            }, 
            {
                "measure": "Minimum Observed Plasma Trough Concentration (Cmin)", 
                "safety_issue": "No", 
                "time_frame": "Week 20"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Week 20"
            }, 
            {
                "measure": "Plasma Decay Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "Week 20"
            }, 
            {
                "measure": "Plasma concentration of PCSK9", 
                "safety_issue": "No", 
                "time_frame": "Week 20"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}